Search

The article offers a preview of the "Dermatidyss®", to improve skin conditions such as atopic dermatitis by reducing stress, enhancing skin hydration, and accelerating healing, from Abyss Ingredients.

EVEN WHEN YOU DO ALL THE RIGHT THINGS TO KEEP YOUR SKIN HEALTHY, rashes, bumps, and redness happen. These are your body's way of telling you something is going on. [...]

Amgen presented topline data from the Phase 3 ROCKET-HORIZON study of focatinlimab for patients with Atopic Dermatitis. The co-primary endpoint for U.S.: ASI-75 and rIGA 0/1 at week 24 and [...]

Baird argues that new data from Amgen (AMGN) on rocatinlimab in atopic dermatitis, or AD, 'look unimpressive,' with a 24 week reduction in EASI-75 'well short' of disease control achieved [...]

Leerink says Amgen disclosed 'underwhelming' Phase 3 data for rocatinlimab in atopic dermatitis and Uplizna in myasthenia gravis in an investor call. Both therapies appear less efficacious than competing, approved [...]

Almirall announced its participation in the 33rd Congress of the European Academy of Dermatology and Venereology, taking place in Amsterdam from September 25 to 28, 2024. This year, Almirall marks [...]

Barclays analyst Balaji Prasad raised the firm's price target on Elanco to $22 from $21 and keeps an Overweight rating on the shares. The shares were down 6% post the [...]

2024 SEP 21 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Eli Lilly and Company (NYSE: LLY) and EVA Pharma announced that the [...]

BD (Becton, Dickinson and Company), a leading global medical technology company, announced the commercial release of the BD Neopak XtraFlow Glass Prefillable Syringe and the latest capacity expansion of the [...]

Elanco Animal Health announced the U.S. FDA has approved Zenrelia, a safe, highly effective, and convenient once-daily oral JAK inhibitor for control of pruritus (itching) associated with allergic dermatitis and [...]

Galderma, the pure-play dermatology category leader, announced it will be showcasing updates from across its industry-leading dermatology portfolio at the 33rd European Academy of Dermatology and Venereology (EADV) congress taking [...]

JPMorgan keeps an Overweight rating on Roivant Sciences (ROIV) after the company announced that Organon (OGN) will acquire Dermavant, which is Roivant 's subsidiary responsible for commercializing Vtama. Roivant will [...]

Ladenburg raised the firm's price target on Corvus Pharmaceuticals to $21 from $12 and keeps a Buy rating on the shares. The firm expanded its model for soquelitinib to include [...]

Wells Fargo initiated coverage of Q32 Bio with an Overweight rating and $95 price target. The firm likes the setup for the shares ahead of the 'two major' Q4 Phase [...]

Eli Lilly (LLY) and EVA Pharma announced that the companies have entered into an agreement to expand access to baricitinib to an estimated 20,000 people in 49 low- to middle-income [...]

Jefferies initiated coverage of Arcutis Biotherapeutics with a Buy rating and $15 price target. Arcutis is a commercial stage biotech company with a topical product, Zoryve, approved for treating plaque [...]

2024 AUG 24 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Turn Therapeutics, a pharmaceutical and medical device company focused on immunology, advanced [...]

Piper Sandler analyst Christopher Raymond raised the firm's price target on Regeneron to $1,242 from $1,166 and keeps an Overweight rating on the shares. Piper's new dermatology survey feedback indicates [...]

Piper Sandler raised the firm's price target on AbbVie (ABBV) to $209 from $196 and keeps an Overweight rating on the shares. Piper's new dermatology survey feedback indicates that while [...]

JPMorgan upgraded UCB to Overweight from Neutral with a price target of EUR 200, up from EUR 150. The analyst expects an expected acceleration in Bimzelx growth driven by new [...]

Truist analyst Joon Lee raised the firm's price target on AnaptysBio to $30 from $20 but keeps a Hold rating on the shares. The firm is adjusting its model, stating [...]

Reports Q2 revenue $30.86M, consensus $29.08M. 'In the second quarter, sales grew by a robust 43% sequentially, highlighting the strength of physician demand for ZORYVE across multiple approved indications, and [...]

RBC Capital analyst Alistair Campbell initiated coverage of Galderma with an Outperform rating and CHF 89 price target. Galderma is a dermatology company with consumer and pharmaceuticals businesses, the analyst [...]

Reports Q2 revenue $23.5M, consensus $17.54M. Cash and investments in marketable securities at June 30, 2024 were $290.6 million as compared to $329.4 million at December 31, 2023. Nektar's cash [...]

Reports Q2 revenue $2.8M, consensus $1.82M. 'With study activities underway for our ATI-2138 Phase 2a trial in moderate to severe atopic dermatitis and the strengthening of our balance sheet through [...]

Wedbush raised the firm's price target on AnaptysBio to $42 from $34 and keeps an Outperform rating on the shares after the company announced Q2 financial results and updated guidance [...]

Arcutis Biotherapeutics announced the commercial launch of ZORYVE cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age 6 in the United [...]

Azitra announced that the U.S. Patent and Trademark Office or USPTO has granted U.S. patent No. 12,036,248, covering future potential pipeline candidates for indications including atopic dermatitis, titled 'Therapeutic treatment [...]

JPMorgan upgraded AnaptysBio to Overweight from Neutral with a price target of $69, up from $29. The firm sees key catalysts in the next 12 months as potentially significant value [...]

Jefferies analyst Farzin Haque assumed coverage of Allakos with a Hold rating and price target of $1, down from $1.50. Allakos is trading below cash following lirentelimab's miss on chronic [...]

Johnson & Johnson reported that it has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics to secure the global rights to NM26, a novel, investigational [...]

Mizuho is 'surprised' Arcutis Biotherapeutics is trading down 5%-6% after yesterday's FDA approval of Zoryve for the treatment of mild to moderate atopic dermatitis, stating that the approval 'significantly improves' [...]

Arcutis Biotherapeutics announced that the Company has been in communication with the U.S. Food and Drug Administration, FDA, regarding its supplemental New Drug Application, sNDA, for roflumilast cream 0.15% for [...]

Q32 Bio announced that it has completed enrollment in the SIGNAL-AD Phase 2 clinical trial of bempikibart for the treatment of persistent, moderate-to-severe atopic dermatitis, or AD. Bempikibart is a [...]

Shares of Kymera Therapeutics (KYMR) are up 10% at $35.09 afterhours after the company announced that following a review of preliminary KT-474 safety and efficacy data by an Independent Data [...]

Kymera Therapeutics (KYMR) announced that following a review of preliminary KT-474 safety and efficacy data by an Independent Data Review Committee, Sanofi (SNY) has informed Kymera that it intends to [...]

After Drug Store News, or DSN, reported that Arcutis Biotherapeutics announced the Food and Drug Administration has approved the supplemental new drug application, or sNDA, for Zoryve cream 0.15% for [...]

Argus analyst Jasper Hellweg keeps a Buy rating and $55 price target on Sanofi while noting that the firm is positive on the company's 'diverse' range of businesses, which include [...]

The article focuses on the long-term management of canine atopic dermatitis, emphasizing the chronic nature of the disease, its clinical diagnosis, and the challenges faced by clinicians in managing it effectively. It discusses the importance of communication with pet owners, the use of allergen-specific immunotherapy, and general support measures such as controlling external parasites, implementing frequent bathing routines, and dietary considerations.

Year after year, atopic dermatitis remains one of the top medical conditions that prompt veterinary visits. (1,2) Yet, very few veterinary schools have dermatologists as faculty, and many veterinary students' [...]

Imbalances in the skin microbiome play a key role in skin disorders; and while most microbiome research to date has been focused on the gastrointestinal tract, more research is being [...]

2024 JUN 29 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on Drugs and Therapies - Antifungals is the subject of [...]

Elanco (ELAN) this morning announced that following feedback from the FDA, it expects the U.S. label of Zenrelia will include a boxed warning on safety based on the outcome of [...]

Johnson & Johnson announced that it has successfully completed the acquisition of Proteologix, a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash with [...]

As previously reported, Guggenheim initiated coverage of Q32 Bio with a Buy rating and $100 price target, citing a positive view of its lead asset bempikibart, which is currently in [...]

Numab Therapeutics AG, a clinical stage biotechnology company advancing a proprietary pipeline of immunology and oncology therapeutics, reported that the Company has entered into a definitive agreement whereby Johnson & [...]

Arcutis Biotherapeutics announced new results from the INTEGUMENT-OLE long-term open-label study of investigational once-daily roflumilast cream 0.15% in adults and children ages 6 years and older with Atopic Dermatitis, or [...]

Goldman Sachs initiated coverage of Apogee Therapeutics with a Not Rated. Apogee is developing biologics in the inflammatory and immune space, initially in atopic dermatitis, asthma and chronic obstructive pulmonary [...]

The company states: 'Jasper Therapeutics announced presentations of data from its preclinical and healthy volunteer studies of briquilimab, as well as trial-in-progress presentations from its BEACON and SPOTLIGHT clinical studies, [...]